

## Special Issue

# New Strategies for Improving the Cognitive Functions in Different Types of Dementia

### Message from the Guest Editors

Dementia and its most common cause, Alzheimer's disease, place a significant burden on health care. Impairment of cognitive function appears in the early stages, but its recognition and treatment are still not completely resolved. The incidence and prevalence of the disease is increasing and is projected to affect nearly 100 million people by 2050. Several studies are underway on the subject; however, the new formulations have not been shown to be effective in severe or advanced stages of the disease, and some of the studied drugs have serious side effects. As a result, only one of the drugs has been approved by the FDA. This molecule is able to delay the clinical decline. However, molecules that would affect or improve cognitive function have not yet been marketed. The aim of our special issue is to publish research results that report new hypotheses related to the pathogenesis of the disease, new pharmacological target molecules, new therapeutic strategies, and possibly alternative treatment options. Furthermore, studies and results about the cognitive function improvement are also hoped for.

### Guest Editors

Dr. Rita Kiss

Prof. Dr. Annamaria Pallag

Dr. Daniel Priksz

### Deadline for manuscript submissions

closed (15 June 2023)



## Future Pharmacology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.7



[mdpi.com/si/129126](https://mdpi.com/si/129126)

*Future Pharmacology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
future-  
pharmacology@mdpi.com

[mdpi.com/journal/  
futurepharmacol](https://mdpi.com/journal/futurepharmacol)





# Future Pharmacology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.7



[mdpi.com/journal/  
futurepharmacol](https://mdpi.com/journal/futurepharmacol)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Fabrizio Schifano

Psychopharmacology, Drug Misuse and Novel Psychoactive  
Substances Research Unit, School of Life and Medical Sciences,  
University of Hertfordshire, Hertfordshire AL10 9AB, UK

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid  
by authors or their institutions.

##### High Visibility:

indexed within ESCI (Web of Science), EBSCO, and other  
databases.

##### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy)